NCT06996236View on ClinicalTrials.gov

Brimonidine Eye Drops in the Prevention of Myopia Progression

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Myopia
Interventions
DRUG

Treatment with brimonidine eye drops 0.025%

Treatment with brimonidine eye drops 0.025%, instilled once a day at night, with simultaneous occlusion of the lower lacrimal punctum to avoid its systemic absorption, for 2 years.

Trial Locations (1)

28035

Hospital Universitario Ramón y Cajal, Madrid

All Listed Sponsors
lead

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER